Citations 0
January 13, 1999

Nevirapine, Didanosine, and Zidovudine for Patients With HIV: The INCAS Trial

Author Affiliations

Margaret A.WinklerMDIndividualAuthorPhil B.FontanarosaMD, Senior EditorsIndividualAuthor


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

JAMA. 1999;281(2):130-131. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-2-jac80019

To the Editor: Dr Montaner and colleagues1 demonstrate that high-level virologic suppression (HIV RNA level <20 copies/mL) can be achieved in 45% of patients with CD4 cell counts between 0.20 and 0.60 × 109/L (200-600/µL) (mean, 0.387×109/L [387/µL]) receiving the combination of zidovudine, didanosine, and nevirapine, suggesting that a subgroup of naive patients can be treated with "protease-sparing" regimens.

First Page Preview View Large
First page PDF preview
First page PDF preview